{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:47:59Z","timestamp":1793969279097,"version":"4.8.0"},"reference-count":198,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"published-print":{"date-parts":[[2020,7,2]]},"DOI":"10.1080\/17425255.2020.1767067","type":"journal-article","created":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T03:00:50Z","timestamp":1588906850000},"page":"583-604","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":28,"title":["An update on efficacy and safety considerations for the latest drugs used to treat irritable bowel syndrome"],"prefix":"10.1080","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1976-6789","authenticated-orcid":false,"given":"Taraneh","family":"Mousavi","sequence":"first","affiliation":[{"name":"Tehran University of Medical Sciences","place":["Tehran, Iran"]},{"name":"School of Pharmacy, Tehran University of Medical Sciences","place":["Tehran, Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5206-6197","authenticated-orcid":false,"given":"Shekoufeh","family":"Nikfar","sequence":"additional","affiliation":[{"name":"Tehran University of Medical Sciences","place":["Tehran, Iran"]},{"name":"Tehran University of Medical Sciences","place":["Tehran, Iran"]},{"name":"School of Pharmacy, Tehran University of Medical Sciences","place":["Tehran, Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0123-1209","authenticated-orcid":false,"given":"Mohammad","family":"Abdollahi","sequence":"additional","affiliation":[{"name":"Tehran University of Medical Sciences","place":["Tehran, Iran"]},{"name":"School of Pharmacy, Tehran University of Medical Sciences","place":["Tehran, Iran"]},{"name":"Tehran University of Medical Sciences","place":["Tehran, Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,6,18]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.14"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/2050640618821804"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X17718677"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2013.19.9.755"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-017-0698-2"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S40245"},{"key":"e_1_3_5_9_1","unstructured":"New rome IV diagnostic criteria for IBS. Philadelphia: IrritableBowelSyndrome.net. 2016 [cited 2020 Jan 4]. Available from: https:\/\/irritablebowelsyndrome.net\/clinical\/new-rome-iv-diagnostic-criteria\/"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2010.13507"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-018-0034-5"},{"key":"e_1_3_5_12_1","first-page":"7","article-title":"Epidemiology of irritable bowel syndrome in Saudi Arabia","volume":"8","author":"Al Harbi S","year":"2018","unstructured":"Al Harbi S. Epidemiology of irritable bowel syndrome in Saudi Arabia. Am J Med Sci. 2018;8:7\u201313.","journal-title":"Am J Med Sci"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X16663396"},{"issue":"1","key":"e_1_3_5_14_1","article-title":"The effect of mesalazine and nortriptyline on patients with irritable bowel syndrome with diarrhea: a randomized clinical trail [Mesalazine, Nortriptyline, Irritable bowel syndrome, Abdominal pain]","volume":"3","author":"Vahedi H","year":"2017","unstructured":"Vahedi H, Mousavi SA, Gholamzadeh S, et al. The effect of mesalazine and nortriptyline on patients with irritable bowel syndrome with diarrhea: a randomized clinical trail [Mesalazine, Nortriptyline, Irritable bowel syndrome, Abdominal pain]. Int J Health Stud. 2017;3(1)","journal-title":"Int J Health Stud"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2016.16138"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/2327-6924.12387"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01116-z"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-015-0243-3"},{"key":"e_1_3_5_19_1","unstructured":"NDA 21-107 LOTRONEX (alosetron hydrochloride) Tablets. Maryland: USFDA; 2000 [cited 2020 Jan 1]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2000\/21107a_Lotronex.cfm"},{"key":"e_1_3_5_20_1","unstructured":"Randomized double-blind placebo-controlled phase 2 trial of BEKINDA (Ondansetron 12 mg bimodal release tablets) for diarrhea predominant irritable bowel syndrome (IBS-D). Maryland: ClinicalTrials.gov; 2016 [cited 2020 Feb 3]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02757105"},{"key":"e_1_3_5_21_1","unstructured":"Study of LX1031 in subjects with non-constipating irritable bowel syndrome. Maryland: ClinicalTrials.gov; 2008 [cited 2020 Jan 30]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT00813098"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.05.005"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/533S116a"},{"key":"e_1_3_5_24_1","unstructured":"Does Welchol (Colesevelam Hydrochloride) Improve Colonic Transit in Diarrhea-predominant Irritable Bowel Syndrome (D-IBS)? (welchol). Maryland: ClinicalTrials.gov; 2009 [cited 2020 Jan 30]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT00911612"},{"key":"e_1_3_5_25_1","unstructured":"Trial to understand efficacy of colesevelam in diarrhea predominant IBS patients with bile acid malabsorption. Maryland: ClinicalTrials.gov; 2017 [cited 2020 Jan 30]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03270085"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h1622"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2019.1593369"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.13023"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-305989"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2012.05208.x"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1533456"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(12)63180-1"},{"key":"e_1_3_5_33_1","unstructured":"Product information: lotronex (alosetron hydrochloride)tablets. Maryland: USFDA; 2000 [cited 2020 Feb 6]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2000\/21107lbl.pdf"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2011.01771.x"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.11.024"},{"key":"e_1_3_5_36_1","unstructured":"New drugs approved in FY 2015. Tokyo: Pharmaceuticals and Medical Devices Agency; 2015 [cited 2020 Feb 6]. Available from: https:\/\/www.pmda.go.jp\/english\/review-services\/reviews\/approved-information\/drugs\/0002.html"},{"key":"e_1_3_5_37_1","unstructured":"Products approved in FY 2008: new drugs. Tokyo: Pharmaceuticals and Medical Devices Agency; 2008 [cited 2020 Jan 29]. Available from: https:\/\/www.pmda.go.jp\/english\/review-services\/reviews\/approved-information\/drugs\/0002.html"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.10.047"},{"issue":"1","key":"e_1_3_5_39_1","first-page":"5","article-title":"Oral presentations","volume":"28","year":"2016","unstructured":"Oral presentations. Neurogastroenterol Motility. 2016;28(S1):5\u2013108.","journal-title":"Neurogastroenterol Motility"},{"key":"e_1_3_5_40_1","unstructured":"Efficacy of ramosetron hydrochloride in male patients with diarrhea-predominant irritable bowel syndrome.Tokyo: UMIN Clinical Trials Registr; 2011 [cited 2020 Feb 11]. Available from: https:\/\/upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000007871"},{"key":"e_1_3_5_41_1","unstructured":"Study on the effect of a combination therapy of H2 receptor antagonist and 5-HT3 receptor antagonist for the treatment of dyspepsia with mild irritable bowel syndrome. Tokyo: UMIN Clinical Trials Registry; 2010 [cited 2020 Feb 11]. Available from: https:\/\/upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000004412"},{"key":"e_1_3_5_42_1","unstructured":"Modification of neurotransmission of brain-gut interactions. Tokyo: UMIN Clinical Trials Registry; 2018 [cited 2020 Feb 11]. Available from: https:\/\/upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000034432"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(18)31888-2"},{"issue":"2","key":"e_1_3_5_44_1","article-title":"OC-090\u2005Different effects of FODMAP (fermentable oligo-, di-, and mono-saccharides, and polyols) components on small bowel water content: an MRI study","volume":"61","author":"Murray K","year":"2012","unstructured":"Murray K, Wilkinson-Smith V, Lam C, et al. OC-090\u2005Different effects of FODMAP (fermentable oligo-, di-, and mono-saccharides, and polyols) components on small bowel water content: an MRI study. Gut. 2012;61(Suppl2):A39.2\u2013A39.","journal-title":"Gut"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-018-2008-z"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(15)31655-3"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.13331"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14031"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.542"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000327"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2017.72"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(19)37015-5"},{"key":"e_1_3_5_53_1","unstructured":"Efficacy of eluxadoline in the treatment of irritable bowel syndrome with diarrhea in patients with inadequate control of symptoms with prior loperamide use. Maryland: ClinicalTrials.gov; 2019 [cited 2020 Feb 11]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02959983"},{"issue":"10","key":"e_1_3_5_54_1","first-page":"S1","article-title":"Meeting abstracts - academy of managed care pharmacy nexus 2018","volume":"24","year":"2018","unstructured":"Meeting abstracts - academy of managed care pharmacy nexus 2018. J Manag Care Spec Pharm. 2018;24(10\u2013aSuppl):S1\u2013S112.","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.116.236547"},{"key":"e_1_3_5_56_1","unstructured":"Study to explore the therapeutic effect of eluxadoline in treating irritable bowel syndrome with diarrhea in children. Maryland: ClinicalTrials.gov; 2017 [cited 2020 Feb 11]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03339128"},{"key":"e_1_3_5_57_1","unstructured":"A phase 2 Randomized Double-Blind Placebo-Controlled Parallel-Group Dose-Ranging Study to Evaluate the Safety and Efficacy of Eluxadoline in Pediatric Patients (Age 12 to 17 Years) with Irritable Bowel Syndrome with Diarrhea (IBS-D). Geneva: international Clinical Trials Registry Platform-WHO; 2018 [cited 2020 Feb 11]. Available from: http:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2017%E2%80%90003770%E2%80%9014%E2%80%90DE"},{"key":"e_1_3_5_58_1","unstructured":"3030-401-002 ELX BAM Study. Maryland: ClinicalTrials.gov; 2018 [cited 2020 Feb 11]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03441581"},{"key":"e_1_3_5_59_1","unstructured":"A comparison of three different treatment options for irritable bowel syndrome (Car-IBS). Maryland: ClinicalTrials.gov; 2016 [cited 2020 Feb 11]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02970591"},{"key":"e_1_3_5_60_1","unstructured":"Viberzi (eluxadoline) tablets. Maryland: U.S. Food and Drug Administration; 2015 [cited 2020 Jan 5]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/206940Orig1s000TOC.cfm"},{"key":"e_1_3_5_61_1","unstructured":"Truberzi: eluxadoline. Amsterdam: European Medicines Agency; 2016 [cited 2020 Jan 14]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/truberzi"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(12)63199-0"},{"key":"e_1_3_5_63_1","unstructured":"A comparison of the effects of ORP-101 versus placebo in adult patients with irritable bowel syndrome with diarrhea (IBS-D). Maryland: ClinicalTrials.gov; 2019 [cited 2020 Feb 11]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04129619"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-4069-x"},{"key":"e_1_3_5_65_1","volume-title":"Enterosgel: a novel organosilicon enterosorbent with a wide range of medical applications. biodefence","author":"Nikolaev VG","year":"2011","unstructured":"Nikolaev VG, editor. Enterosgel: a novel organosilicon enterosorbent with a wide range of medical applications. biodefence. Dordrecht: Springer Netherlands; 2011."},{"key":"e_1_3_5_66_1","unstructured":"Randomised double-blind placebo-controlled multi-centre study to assess the efficacy tolerability and safety of Enterosgel\u00ae in the treatment of Irritable Bowel Syndrome with Diarrhoea (IBS-D) in adults (RELIEVE IBS-D). Geneva: International Clinical Trials Registry Platform-WHO; 2017 [cited 2020 Feb 5]. Available from: http:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=ISRCTN17149988"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04818.x"},{"key":"e_1_3_5_68_1","unstructured":"Olorinab in IBS-C and IBS-D (CAPTIVATE). Maryland: ClinicalTrials.gov; 2019 [cited 2020 Feb 11]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04043455"},{"key":"e_1_3_5_69_1","unstructured":"HIGHLIGHTS OF PRESCRIBING INFORMATION: rifaximin. Maryland: ClinicalTrials.gov; 2017 [cited 2020 Feb 5]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021361s023lbl.pdf"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12664-013-0383-5"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2018.1460013"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.336_10"},{"issue":"1","key":"e_1_3_5_73_1","first-page":"S739","article-title":"Functional bowel disease","volume":"110","year":"2015","unstructured":"Functional bowel disease. Am J Gastroenterol. 2015;110(Suppl 1):S739\u201366.","journal-title":"Am J Gastroenterol"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12735"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(18)31894-8"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(15)30242-0"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(15)32236-8"},{"issue":"1","key":"e_1_3_5_78_1","first-page":"S236","article-title":"Functional bowel disease","volume":"111","year":"2016","unstructured":"Functional bowel disease. Am J Gastroenterol. 2016;111(S1):S236\u2013S260.","journal-title":"Am J Gastroenterol"},{"key":"e_1_3_5_79_1","author":"Indian Society of Gastroenterology","year":"2013","unstructured":"Indian Society of Gastroenterology. Indian J Gastroenterol. 2013.","journal-title":"Indian J Gastroenterol"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-018-5344-5"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2015.30.6.757"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-014-3157-8"},{"issue":"1","key":"e_1_3_5_83_1","first-page":"1","article-title":"Abstracts-APASL 2013","volume":"7","year":"2013","unstructured":"Abstracts-APASL 2013. Hepatol Int. 2013;7(Suppl 1):1\u2013754.","journal-title":"Hepatol Int"},{"key":"e_1_3_5_84_1","unstructured":"Effects of continuous treatment with rifaximin and probiotics on the gut microbiota of patients with IBS-D. Maryland: ClinicalTrials.gov; 2019 [cited 2020 Feb 14]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04074421"},{"issue":"8","key":"e_1_3_5_85_1","first-page":"1","article-title":"Advances in IBS 2016: A review of current and emerging data","volume":"12","author":"Schoenfeld PS","year":"2016","unstructured":"Schoenfeld PS. Advances in IBS 2016: A review of current and emerging data. Gastroenterol Hepatol. 2016;12(8 Suppl 3):1\u201311.","journal-title":"Gastroenterol Hepatol"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2019.1688784"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.197"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1318.2009.01990.x"},{"key":"e_1_3_5_89_1","unstructured":"Highlights of prescribing information: tegaserod. Maryland: U.S. Food and Drug Administration; 2019 [cited 2020 Feb 6]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021200Orig1s015lbl.pdf"},{"key":"e_1_3_5_90_1","unstructured":"Zelnorm (tegaserod). Amsterdam: European Medicines Agency; 2009 [cited 2020 Feb 5]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zelnorm"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(19)38890-0"},{"key":"e_1_3_5_92_1","unstructured":"Questions and answers on recommendation for refusal of marketing application for Zelnorm. Amsterdam: European Medicines Agency; 2006 [cited 2020 Feb 5]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/questions-answers-recommendation-refusal-marketing-authorisation-zelnorm_en.pdf"},{"key":"e_1_3_5_93_1","unstructured":"Constella. Amsterdam: European Medicines Agency; 2012 [cited 2020 Feb 5]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/constella"},{"key":"e_1_3_5_94_1","unstructured":"New drugs approved in FY 2016. Tokyo: Pharmaceuticals and Medical Devices Agency; 2016 [cited 2020 Feb 22]. Available from: https:\/\/www.pmda.go.jp\/english\/review-services\/reviews\/approved-information\/drugs\/0002.html"},{"key":"e_1_3_5_95_1","unstructured":"CONSTELLA linaclotide 290 microgram hard capsule bottle. Symonston: Therapeutic Goods Administration; 2019 [cited 2020 Feb 23]. Available from: http:\/\/search.tga.gov.au\/s\/search.html?collection=tga-artg&profile=record&meta_i=297704"},{"key":"e_1_3_5_96_1","unstructured":"Highlights of prescribing information: plecanatide. Maryland: U.S. Food and Drug Administration; 2018 [cited 2020 Jan 5]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/208745s001lbl.pdf"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.255"},{"issue":"2","key":"e_1_3_5_98_1","article-title":"PTU-151\u2005Small bowel ultrasound: diagnostic yield in established small bowel Crohn\u2019s disease","volume":"61","author":"Pearl DS","year":"2012","unstructured":"Pearl DS, Higginson A, Quine A. PTU-151\u2005Small bowel ultrasound: diagnostic yield in established small bowel Crohn\u2019s disease. Gut. 2012;61(Suppl2):A247.1-A247.","journal-title":"Gut"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.03.233"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.254"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-307263.427"},{"key":"e_1_3_5_102_1","doi-asserted-by":"crossref","DOI":"10.14309\/00000434-201410002-01791","article-title":"Two Years on Linaclotide: tolerability and Treatment Satisfaction in IBS-C Patients With and Without Diarrhea: presidential Poster: 1791","volume":"109","author":"Chey W","year":"2014","unstructured":"Chey W, Shiff S, Schneier H, et al. Two Years on Linaclotide: tolerability and Treatment Satisfaction in IBS-C Patients With and Without Diarrhea: presidential Poster: 1791. Am J Gastroenterol. 2014;109:S530.","journal-title":"Am J Gastroenterol"},{"key":"e_1_3_5_103_1","unstructured":"Highlights of prescribing information: linaclotide. Maryland: U.S. Food and Drug Administration; 2017 [cited 2020 Jan 13]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/202811s010lbl.pdf"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(17)34374-3"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.13275"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(18)33289-X"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(19)38885-7"},{"key":"e_1_3_5_108_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0026-7"},{"key":"e_1_3_5_109_1","unstructured":"The plecanatide irritable bowel syndrome with constipation study (IBS-C). Maryland: ClinicalTrials.gov; 2015 [cited 2020 Feb 13]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02387359"},{"key":"e_1_3_5_110_1","unstructured":"Second plecanatide study in irritable bowel syndrome with constipation (IBS-C). Maryland: ClinicalTrials.gov; 2015 [cited 2020 Feb 13]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02493452"},{"key":"e_1_3_5_111_1","unstructured":"Efficacy and safety of plecanatide in children 6 to <18 years of age with irritable bowel syndrome with constipation (IBS-C). Maryland: ClinicalTrials.gov; 2018 [cited 2020 Feb 13]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03596905"},{"key":"e_1_3_5_112_1","unstructured":"A safety and efficacy study of a range of linaclotide doses administered orally to children ages 7\u201317 years with irritable bowel syndrome with constipation (LIN-MD-63). Maryland: ClinicalTrials.gov; 2015 [cited 2020 Feb 13]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02559817"},{"key":"e_1_3_5_113_1","unstructured":"A study of the effect of linaclotide on abdominal girth in participants with IBS-C. Maryland: ClinicalTrials.gov; 2016 [cited 2020 Feb 13]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02837783"},{"key":"e_1_3_5_114_1","unstructured":"A phase 4 single-centre randomised double-blind placebo-controlled parallel-group fixed-dose study of the effect of linaclotide on abdominal girth in participants with irritable bowel syndrome with constipation. Amsterdam: EU Clinical Trials Register; 2016 [cited 2020 Feb 13]. Available from: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-000818-29\/GB#G"},{"key":"e_1_3_5_115_1","unstructured":"Highlights of prescribing information: lubiprostone. Maryland: U.S. Food and Drug Administration; 2012 [cited 2020 Jan 1]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021908s010lbl.pdf"},{"key":"e_1_3_5_116_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13807"},{"key":"e_1_3_5_117_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04983.x"},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03881.x"},{"key":"e_1_3_5_119_1","unstructured":"Evaluation of the efficacy and safety of lubiprostone in adults with mixed or unsubtyped irritable bowel syndrome. Maryland: ClinicalTrials.gov; 2015 [cited 2020 Feb 13]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02544152"},{"key":"e_1_3_5_120_1","doi-asserted-by":"crossref","DOI":"10.1038\/ajg.2013.270","article-title":"Performance differences between Zegerid\u00ae and PrilosecTM dosage forms: a comparative bioavailability study","volume":"108","author":"Kearbey J","year":"2013","unstructured":"Kearbey J, McGraw T, O\u2019Mullane J, et al. Performance differences between Zegerid\u00ae and PrilosecTM dosage forms: a comparative bioavailability study. Am J Gastroenterol. 2013;108:S561.","journal-title":"Am J Gastroenterol"},{"key":"e_1_3_5_121_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2011.01776.x"},{"key":"e_1_3_5_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(12)61691-6"},{"key":"e_1_3_5_123_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2011.01668.x"},{"key":"e_1_3_5_124_1","unstructured":"Comparison of drug efficacy between linaclotide and lubiprostone in constipation-predominant irritable bowel syndrome patients. Geneva: International Clinical Trials Registry Platform-WHO; 2017 [cited 2020 Feb 13]. Available from: http:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN%E2%80%90UMIN000028709"},{"key":"e_1_3_5_125_1","unstructured":"Highlights of prescribing information: tenapanor. Maryland: U.S. Food and Drug Administration; 2019 [cited 2020 Feb 6]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211801s000lbl.pdf"},{"key":"e_1_3_5_126_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(18)34452-4"},{"key":"e_1_3_5_127_1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000516"},{"key":"e_1_3_5_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(15)30637-5"},{"key":"e_1_3_5_129_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2017.41"},{"key":"e_1_3_5_130_1","unstructured":"Effects of ROSE-010 on GI transit in constipation predominant irritable bowel syndrome (C-IBS) patients.Maryland: ClinicalTrials.gov; 2010 [cited 2020 Feb 5]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01056107"},{"key":"e_1_3_5_131_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00076.2012"},{"key":"e_1_3_5_132_1","doi-asserted-by":"publisher","DOI":"10.1177\/2050640616663689"},{"key":"e_1_3_5_133_1","doi-asserted-by":"publisher","DOI":"10.5056\/jnm16203"},{"key":"e_1_3_5_134_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(13)60576-4"},{"key":"e_1_3_5_135_1","unstructured":"Histamine 1 receptor antagonist ebastine as novel treatment in IBS. Amsterdam: EU Clinical Trials Register 2013 [cited 2020 Feb 6]. Available from: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-001199-39\/BE"},{"key":"e_1_3_5_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.10.020"},{"key":"e_1_3_5_137_1","unstructured":"A study of the effect of SYN-010 on subjects with IBS-C. Maryland: ClinicalTrials.gov; 2015 [cited 2020 Feb 5]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02495623"},{"key":"e_1_3_5_138_1","unstructured":"A single-dose open-label study to evaluate the sustainability of the effects of SYN-010 in patients with IBS-C. Maryland: ClinicalTrials.gov; 2015 [cited 2020 Feb 5]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02493036"},{"key":"e_1_3_5_139_1","unstructured":"Irritable bowel syndrome (IBS) treatment with H1-receptor antagonists. Maryland: ClinicalTrials.gov; 2010 [cited 2020 Feb 5]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01144832"},{"key":"e_1_3_5_140_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-017-1383-5"},{"key":"e_1_3_5_141_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.07.052"},{"issue":"5","key":"e_1_3_5_142_1","first-page":"1","article-title":"Oral abstracts","volume":"26","year":"2011","unstructured":"Oral abstracts. J Gastroenterol Hepatol. 2011;26(s5):1\u201315.","journal-title":"J Gastroenterol Hepatol"},{"key":"e_1_3_5_143_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04730.x"},{"key":"e_1_3_5_144_1","unstructured":"Ibodutant for relief of irritable bowel syndrome (IRIS). Maryland: ClinicalTrials.gov; 2008 [cited 2020 Jan 30]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT00761007?view=record"},{"key":"e_1_3_5_145_1","unstructured":"Ibodutant for relief of irritable bowel syndrome with diarrhoea (IBS-D)(IRIS-2). Maryland: ClinicalTrials.gov; 2011 [cited 2020 Jan 30]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01303224"},{"key":"e_1_3_5_146_1","unstructured":"Menarini Group. Ibodutant for relief of irritable bowel syndrome with diarrhoea (IBS-D)(IRIS-2). Maryland: ClinicalTrials.gov; [cited 2020 Jan 4]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01303224"},{"key":"e_1_3_5_147_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(13)62091-0"},{"key":"e_1_3_5_148_1","unstructured":"12-week efficacy and safety study of ibodutant in women with irritable bowel syndrome with diarrhea (IBS-D)(IRIS-3). Maryland: ClinicalTrials.gov; 2016 [cited 2020 Jan 30]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02107196"},{"key":"e_1_3_5_149_1","unstructured":"52-week efficacy and safety study of ibodutant in women with irritable bowel syndrome with diarrhea (IBS-D)(IRIS-4). Maryland: ClinicalTrials.gov; 2017 [cited 2020 Jan 30]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02120027"},{"key":"e_1_3_5_150_1","doi-asserted-by":"publisher","DOI":"10.5056\/jnm19160"},{"key":"e_1_3_5_151_1","doi-asserted-by":"publisher","DOI":"10.23736\/S1121-421X.18.02530-8"},{"key":"e_1_3_5_152_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-015-3858-7"},{"key":"e_1_3_5_153_1","unstructured":"Menthae piperitae aetheroleum.Amsterdam: european Medicines Agency; 2019 [cited 2020 Feb 23]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/herbal\/menthae-piperitae-aetheroleum"},{"key":"e_1_3_5_154_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-009-0854-9"},{"key":"e_1_3_5_155_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.08.026"},{"key":"e_1_3_5_156_1","unstructured":"PRODUCT INFORMATION: COLOFAC. Symonston: therapeutic Goods Administration; 2017 [cited 2020 Feb 22]. Available from: https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/PICMI?OpenForm&t=&q=mebeverine"},{"key":"e_1_3_5_157_1","doi-asserted-by":"publisher","DOI":"10.15403\/jgld.2014.1121.234.mibs"},{"key":"e_1_3_5_158_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v16.i5.547"},{"key":"e_1_3_5_159_1","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_522_19"},{"key":"e_1_3_5_160_1","doi-asserted-by":"publisher","DOI":"10.4103\/1319-3767.145331"},{"key":"e_1_3_5_161_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15077"},{"key":"e_1_3_5_162_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2015.01.015"},{"key":"e_1_3_5_163_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharep.2017.05.014"},{"key":"e_1_3_5_164_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.11.279"},{"key":"e_1_3_5_165_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30324-3"},{"key":"e_1_3_5_166_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028014528151"},{"issue":"9","key":"e_1_3_5_167_1","first-page":"Online","article-title":"Effectiveness of selective serotonin reuptake inhibitors for irritable bowel syndrome","volume":"92","author":"Wilkins T","year":"2015","unstructured":"Wilkins T, Agabin E, Blake L. Effectiveness of selective serotonin reuptake inhibitors for irritable bowel syndrome. Am Fam Physician. 2015;92(9):Online.","journal-title":"Am Fam Physician"},{"key":"e_1_3_5_168_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127815"},{"issue":"1","key":"e_1_3_5_169_1","first-page":"71","article-title":"Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: a meta-analysis of randomized controlled trials","volume":"4","author":"Rahimi R","year":"2008","unstructured":"Rahimi R, Nikfar S, Abdollahi M. Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: a meta-analysis of randomized controlled trials. Arch Med Sci. 2008;4(1):71\u201376.","journal-title":"Arch Med Sci"},{"key":"e_1_3_5_170_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.50.1.78"},{"key":"e_1_3_5_171_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.09.008"},{"key":"e_1_3_5_172_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.1548"},{"key":"e_1_3_5_173_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.3636"},{"key":"e_1_3_5_174_1","first-page":"352","article-title":"Doxepin is more effective than nortriptyline and placebo for the treatment of diarrhea-predominant irritable bowel syndrome: a randomized triple-blind placebo-controlled trial","volume":"69","author":"Ghadir MR","year":"2011","unstructured":"Ghadir MR, Habibinejad H, Heidari A, et al. Doxepin is more effective than nortriptyline and placebo for the treatment of diarrhea-predominant irritable bowel syndrome: a randomized triple-blind placebo-controlled trial. Tehran Univ Med J. 2011;69:352\u2013358.","journal-title":"Tehran Univ Med J"},{"key":"e_1_3_5_175_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-30726-3_21"},{"key":"e_1_3_5_176_1","doi-asserted-by":"publisher","DOI":"10.3109\/13651501.2013.838632"},{"key":"e_1_3_5_177_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i22.6759"},{"key":"e_1_3_5_178_1","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2012.29396"},{"key":"e_1_3_5_179_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2020.01.142"},{"key":"e_1_3_5_180_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i10.3072"},{"key":"e_1_3_5_181_1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4103\/sjg.SJG_384_19","article-title":"Efficacy and safety of probiotics in irritable bowel syndrome: A systematic review and meta-analysis","volume":"26","author":"Sun JR","year":"2020","unstructured":"Sun JR, Kong CF, Qu XK, et al. Efficacy and safety of probiotics in irritable bowel syndrome: A systematic review and meta-analysis. Saudi J Gastroenterol. 2020;26:66\u201377.","journal-title":"Saudi J Gastroenterol"},{"key":"e_1_3_5_182_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2019.04.032"},{"key":"e_1_3_5_183_1","unstructured":"ARTG: probiotics.Symonston: therapeutic Goods Administration; 2020 [cited 2020 Feb 23]. Available from: https:\/\/tga-search.clients.funnelback.com\/s\/search.html?query=probiotics+FOR+IBS&collection=tga-artg"},{"key":"e_1_3_5_184_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i7.589"},{"key":"e_1_3_5_185_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13540"},{"key":"e_1_3_5_186_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14817"},{"key":"e_1_3_5_187_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11655-019-3030-x"},{"key":"e_1_3_5_188_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(18)33288-8"},{"key":"e_1_3_5_189_1","doi-asserted-by":"publisher","DOI":"10.1159\/000485410"},{"key":"e_1_3_5_190_1","doi-asserted-by":"publisher","DOI":"10.5402\/2011\/206103"},{"key":"e_1_3_5_191_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023641"},{"key":"e_1_3_5_192_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-318160"},{"key":"e_1_3_5_193_1","doi-asserted-by":"crossref","unstructured":"Li YH Gupta PJ Sawant R et al. A cost-effectiveness comparison of alosetron eluxadoline and rifaximin in the treatment of irritable bowel syndrome with diarrhea. Pharm Pharmacol Int J 2016;4(6):450-458.","DOI":"10.15406\/ppij.2016.04.00095"},{"key":"e_1_3_5_194_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15001"},{"key":"e_1_3_5_195_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2014.979291"},{"key":"e_1_3_5_196_1","unstructured":"CDR Pharmacoeconomic Review Report for Constella - Cadth. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2015 [cited 2020 Feb 24]. Available from: https:\/\/www.cadth.ca\/sites\/default\/files\/cdr\/pharmacoeconomic\/SR0409_Constella_PE_Report.pdf"},{"key":"e_1_3_5_197_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.08.021"},{"key":"e_1_3_5_198_1","first-page":"36","article-title":"Controversies and recent developments of the low-FODMAP diet","volume":"13","author":"Hill P","year":"2017","unstructured":"Hill P, Muir J, Gibson P. Controversies and recent developments of the low-FODMAP diet. Gastroenterol Hepatol. 2017;13:36\u201345.","journal-title":"Gastroenterol Hepatol"},{"key":"e_1_3_5_199_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14650"},{"key":"e_1_3_5_200_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastrohep.2015.07.009"}],"container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2020.1767067","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:46:30Z","timestamp":1770943590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425255.2020.1767067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,18]]},"references-count":198,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7,2]]}},"alternative-id":["10.1080\/17425255.2020.1767067"],"URL":"https:\/\/doi.org\/10.1080\/17425255.2020.1767067","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"value":"1742-5255","type":"print"},{"value":"1744-7607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-03-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}